Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010257 · ClinicalTrials.gov registry record · Phase 2
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00010257 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 46 participants.
The verdict
NCT00010257, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patients who have advanced thymoma.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2001-06-19 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010257
The ClinicalTrials.gov registry entry for NCT00010257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00010257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010257 about?
NCT00010257 is a clinical study titled "Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patient...
What is the current status of trial NCT00010257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2001-06-19. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00010257?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00010257?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.